Related Experiment Video
Updated: Jul 16, 2026
05:58
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
Colchicine in coronary artery disease: limitations and challenges
Luca Ferdinando Scungio1, Theodora Nikiforou1, Carolina Pascucci1
1Cardio Center, IRCCS Humanitas Research Hospital, Rozzano, Milan; and Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Clinical and Experimental Rheumatology
|July 15, 2026
Summary
Colchicine shows potential for secondary prevention in coronary artery disease, particularly for chronic conditions. However, its use in acute settings and routine practice requires further research due to inconsistent results and safety concerns.
Area of Science:
- Cardiology
- Pharmacology
- Inflammation Research
Background:
- Colchicine is being investigated as an anti-inflammatory agent for secondary prevention in coronary artery disease (CAD).
- Its efficacy and safety in various CAD patient populations and clinical scenarios are still under evaluation.
Purpose of the Study:
- To review the current evidence on colchicine's role in secondary prevention for coronary artery disease.
- To identify limitations and challenges hindering its widespread clinical adoption.
Main Methods:
- Systematic review of randomized controlled trials investigating colchicine in CAD.
- Analysis of efficacy, safety, and tolerability data across different patient subgroups and treatment settings.
Main Results:
- Colchicine demonstrates consistent benefits in chronic coronary syndromes and selected post-myocardial infarction patients.
- Evidence is less convincing for acute coronary syndromes and percutaneous coronary intervention (PCI)-related settings.
- Trial heterogeneity, lack of biomarker-guided selection, and safety concerns pose challenges.
Conclusions:
- Colchicine may benefit selected CAD patients rather than serving as a universal treatment.
- Further research is needed to optimize its clinical use, timing, duration, and personalize its application.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:30Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...